GSK’s triple COPD combination therapy meets two co-primary endpoints in phase III study

GlaxoSmithKline’s (GSK) investigational once-daily closed triple combination therapy was superior to AstraZeneca’s twice-daily Symbicort Turbohaler (budesonide/formoterol 400/12 mcg) in a phase III study in patients with chronic obstructive pulmonary disease (COPD). http://clinicaltrials.pharmaceutical-business-review.com/news/gsks-triple-copd-combination-therapy-meets-two-co-primary-endpoints-in-phase-iii-study-210616-4929021